CAF 家族佐剂的免疫相关性。

Immunocorrelates of CAF family adjuvants.

机构信息

Department of Infectious Disease Immunology, Statens Serum Institut, Artillerivej 5, DK-2300, Copenhagen S, Denmark.

出版信息

Semin Immunol. 2018 Oct;39:4-13. doi: 10.1016/j.smim.2018.10.003. Epub 2018 Nov 2.

DOI:10.1016/j.smim.2018.10.003

Abstract

The development of the CAF family adjuvant was initiated around 20 years ago when Statens Serum Institut was preparing its first generation protein based recombinant subunit vaccine against tuberculosis for clinical testing, but realized that there were no clinically relevant adjuvants available that would support the strong CMI response needed. Since then the aim for the adjuvant research at Statens Serum Institut has been to provide adjuvants with distinct immunogenicity profiles correlating with protection for any given infectious disease. Two of the adjuvants CAF01 and CAF09 are currently being evaluated in human clinical trials. The purpose of this review is to give an overview of the immunocorrelates of those CAF adjuvants furthest in development. We further aim at giving an overview of the mechanism of action of the CAF adjuvants.

摘要

CAF 佐剂家族的开发始于大约 20 年前，当时 Statens Serum Institut 正在为临床测试准备第一代针对结核病的基于蛋白质的重组亚单位疫苗，但意识到没有可用于支持所需强烈细胞免疫反应的临床相关佐剂。从那时起，Statens Serum Institut 的佐剂研究目标一直是为任何给定的传染病提供具有独特免疫原性特征并与保护相关的佐剂。目前正在对 CAF01 和 CAF09 这两种佐剂进行人体临床试验评估。本综述的目的是概述那些处于开发后期的 CAF 佐剂的免疫相关性。我们还旨在概述 CAF 佐剂的作用机制。